VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology
News Dec 19, 2008
VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.
The licensed patents result from the research of stem cell pioneer Dr. James Thompson of the University of Wisconsin Stem Cell & Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research.
The license will accelerate VistaGen’s commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical R&D productivity for the pharmaceutical industry.
“This agreement with WARF is another critical step in our strategy to become a ‘one-stop-shop’ for the world’s premier stem cell differentiation system,” said Dr. Ralph Snodgrass, VistaGen’s CEO. “It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development. When combined with our strong stem cell-based intellectual property estate, the key terms of the new license provide a strong foundation to support our commercial programs focused on high-end R&D services, strategic discovery collaborations and enabling licenses.”
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE